MenaQ7® Natural Vitamin K Chosen as Finalist for Nutrition Business Technology Award

OSLO, NORWAY -- NattoPharma ASA (NATTO: Oslo Axess) has announced that its product, MenaQ7Crystals brand vitamin K2 menaquinone-7 (MK-7), the leading MK-7 ingredient, has been selected as a finalist -- one of three -- for Nutrition Business Technology's "Most Effective Product Development Strategy category, as part of its annual awards program presented at Vitafoods, Europe's leading nutritional and food tradeshow.

Specifically, MenaQ7Crystals and NattoPharma are currently on the short list for the "Most Effective Product Development Strategy" category. The entries for the NBT award in this specific category ( nbtawards.com/nbta/enteringtheawards.asp )must demonstrate how the program was implemented to incorporate new product strategy in response to market needs. The entries must also provide evidence of the identification and commercialization of technologies that address emerging trends and new product requirements.  MenaQ7Crystals addresses a growing recognition by the global health care community for high purity, stable and well-researched vitamin K2, menaquinone-7 for supplemental and food use, to prevent osteoporosis, cardiovascular disease and to provide safe distribution of calcium in the body, especially in aging populations. The breakthrough clinical study on NattoPharma’s brand of MenaQ7 was published  in March 2013 in the journal Osteoporosis International . Pending manuscripts on MenaQ7 brand are on cardiovascular disease protection and prevention of metabolic functions deterioration with aging.

Frode M. Bohan, NattoPharma Chairman, comments, "This prestigious award nomination marks the launch of our breakthrough technology, MenaQ7Crystals. This ingredient provides the market with several unique firsts -- it is the most bioactive form of natural vitamin K2 menaquinone-7 available, it is the first natural MK-7 with its own clinical trial demonstrating therapeutic benefits for bone and heart health, and it is the only patented natural vitamin K2 product. “

Hogne Vik, MD, PhD, MBA, CEO of NattoPharma, adds, "We are honored to receive this recognition from NBT and Vitafoods as a result of many years of research and development. This nomination along with the recent publication of our three-year study in Osteoporosis International, gives the market confidence about the important role of MK-7 (MenaQ7Crystals) in global human health, and will also help energetically develop the commercial market for MK-7, a much needed nutrient for people worldwide."

About MenaQ7® brand and MenaQ7Crystals ™

MenaQ7Crystals ™ provides natural vitamin K2 whereby vitamin K2 is manufactured using Bacillus licheniformis in a soy‐free fermentation process. This process has the capacity of producing the highly pure and bio‐available form of vitamin K2, menaquinone‐7 (MK‐7) in crystallized form. MenaQ7® brand is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending. For more information, visit www.menaq7.com .

About NattoPharma

As a biotechnology-based nutraceutical company, NattoPharma is the worldwide innovator and leader of Vitamin K2 menaquinone-7. Its brand MenaQ7® is supported by a global IPR portfolio and revolutionary research substantiating clear efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in an exclusive research and development collaboration with VitaK, University in Maastricht, The Netherlands, working to substantiate the health benefits of natural vitamin K2.

For more information, please contact:

Dr. Hogne Vik (CEO)
hogne@nattopharma.com ,
Phone:
+47 975 35 326

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.